Entity Name: Hebrew Home for Aged Disabled; dba Jewish Home, San Francisco
Address: 302 Silver Ave, San Francisco CA 94112
Type of organization: Skilled Nursing (D/P), Acute Psychiatric Hospital
Tax exempt status: 501c(3) corporation
Date of incorporation: 10/16/1889
Interim Chief Financial Officer
Entity Identification Number (EIN) #94-0545320
DUNS No.: 020004693
Congressional District: CA-008
DHHS F&A Agreement date: 6/05/2012
DHHS site: Division of Cost Allocation
Dept. of Health & Human Services
90 7th Street, Suite 4-600
San Francisco, CA 94103-6705
To respond to the future challenges of our older adults’ changing healthcare needs, the Jewish Home has launched a $5 million Campaign for Research on Aging. Our goal is to have a world-class research center that will develop and coordinate clinical research devoted to diseases and conditions associated with very old age.
Research enables us to evaluate approaches to care, to assess current therapies and environments, and to design and evaluate new therapies and programs. Through the creation of a center composed of multidisciplinary researchers, we are hoping to minimize the adverse consequences of aging.
The Jewish Home’s Long-Term Care Research Center was formed in 1997 in collaboration with the (Goldman) Institute on Aging. Janice B. Schwartz, M.D., was recruited in September 2001 as director of Research at the Jewish Home. In 2005, the Jewish Home’s research activities became independent under the direction of the Research department, culminating in the creation of our current Center for Research on Aging.
The goal of our research center is to discover and disseminate information that will result in improved care of older people, especially for the frail elderly. We hope to improve both the use of existing medical therapies and to develop new therapeutic approaches. We focus our research on common disorders occurring in older people, as well as on problems unique to aging populations. Our role is to bridge the gap between scientific discovery and the translation of our and others’ discoveries to beneficial use in older people.
The goal of this project is to determine how age, gender, or ethnicity can affect the removal of medications from the body. Among the highlights of Dr. Schwartz’s findings are that women metabolize some, but not all, drugs faster than men; women and men require different doses of medicine; and hormone replacement therapy in women does not affect drug metabolism or responses.
The overall hypothesis is that use of genetic information in combination with demographic and concomitant medication administration information will provide better estimates of drug dosing requirements than consideration of demographic and concomitant medication administration information alone in very old patients. Warfarin is the first medication to be studied. It is hoped that this would allow improved dosing during initiation of warfarin to older patients and decrease unwanted bleeding complications and that the time to reach a desired anticoagulation level will be reduced.
This project seeks to identify moments of meaningful connection between caregivers and nursing home residents and to explore the underlying processes that foster relationships and social connections. An understanding of these processes may contribute to the development of clinical care models that enhance the quality of life of institutionalized adults with dementia.
This study will determine the effects of vitamin D supplements on how quickly the body clears a commonly prescribed cholesterol medication, Lipitor (atorvastatin). Levels of Lipitor will be measured in the blood, and the levels of blood lipids will also be evaluated. Identification of agents that may alter drug metabolism is important for optimizing drug therapy, especially in individuals who take multiple medications and supplements.
Preliminary research data suggest that vitamin D supplements lower blood LDL-cholesterol and total cholesterol levels. If further investigation supports its effectiveness in lowering blood cholesterol levels, vitamin D administration could serve as a valuable addition or alternative to existing treatments for hyperlipidemia. The aim of this research is to detail the effects of vitamin D supplementation on blood lipid levels.
The overall hypothesis is that two critical causes of immunosenescence (aging-associated changes in immunity) are dysregulated generation of inflammatory interleukins (immune proteins) by T lymphocytes and production of anti-lymphocyte autoantibodies; that both are susceptible to correction by existing forms of therapy. This investigation is designed to study in the laboratory T lymphocytes from the blood of healthy aged patients in comparison to those of healthy young matched controls. The numbers of different types of T lymphocytes will be quantified and their functions assessed in vitro, including generation of a range of interleukins. Subject plasma will be studied for the presence and characteristics of anti-lymphocyte autoantibodies.
Hopes for developing effective treatments for Alzheimer disease (AD) rest on clinical research, that will need to enroll AD patients, many of whom lack capacity to consent to research. This project will study how responsible parties or agents make decisions about entering Alzheimer disease patients into research projects. It will present protocols of varying risk and benefit levels (1) to determine influences on proxies’ research decisions and perceptions of research and (2) to examine potential influences on the decision making abilities of the proxies themselves.
The overall goal is to improve the use of medications for older people with multiple medical disorders. Our first step will be to identify the prevalence, type, and severity of prescribing problems in older people with defined patterns of multiple co-morbidities (“morbidotypes”) from databases of representative large groups of older men and women (Veterans Administration databases for older men and Nursing Home database(s) for older and very old women and men). The next step will be to develop “potentially optimized prescribing (POP)” algorithms that would be predicted to result in fewer medications prescribed, fewer unwanted effects,be appropriate and efficacious for the older patient. The development process will consider clinical practice guidelines for each disorder, pharmacologic properties and interactions of medications used for the disorders (pharmacokinetic and pharmacodynamic), and geriatric conditions (function, projected length of life, care for vulnerable elderly) that would modify the approach to treatment of the disorder. The proposed optimized therapeutic combinations will then be evaluated and modified by experts from medical disciplines of the practice guidelines, clinical pharmacology and pharmacy, geriatrics, and health care utilization. The potentially optimized regimens identified will be used to design a subsequent comparative effectiveness study of the optimized combinations and “usual” therapy.
The Jewish Home is one of four nursing homes enrolling residents in this project, based at the University of Minnesota. The goals are to determine appropriate levels for optimal outcomes, identify factors associated with instability of concentrations, determine if new AEDs are associated with fewer adverse events, evaluate the usefulness of measuring AEDs, and determine the total cost (drug, hospitalizations, nursing time, etc.) of AED therapy in the nursing-home setting, where they may be used for the treatment of pain disorders, in addition to seizure disorders.
The primary objective of this research study is to demonstrate that implementation of an Antimicrobial Stewardship Program (ASP) in stand-alone long-term care facilities (LTCFs), utilizing the syndromic approach targeting urinary tract infections (UTIs), is feasible. Secondary objectives are to demonstrate the efficacy of an ASP in LTCFs by comparing pre- and post-ASP susceptibility profiles, antimicrobial utilization data, and antimicrobial-related adverse effects. Lessons learned will be documented and used as a guideline for implementing ASPs in stand-alone LTCFs.
Applications for research at the Jewish Home are welcomed. Researchers considering projects at the Jewish Home are encouraged to before completing the application for research at the Jewish Home.
Applications undergo review by the Jewish Home Research Committee but must have a licensed Institutional Review Board approval or Committee on Human Research Approval before they can be considered.